# Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset

Study · id `cardio:ct-nct07324837` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07324837](<https://clinicaltrials.gov/study/NCT07324837>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07324837

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1050 participants.

## Technical summary

Registry record NCT07324837. Randomized; triple masking; primary purpose treatment. Start 2026-06-09 (actual); primary completion 2028-11-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1050 participants (planned count; ClinicalTrials.gov record NCT07324837, source copy `cardio:ctgov-nct07324837-2026-11-12`, retrieved 2026-11-18)
- Started: 2026-06-09 (actual) (ClinicalTrials.gov record NCT07324837, source copy `cardio:ctgov-nct07324837-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2028-11-01 (anticipated) (ClinicalTrials.gov record NCT07324837, source copy `cardio:ctgov-nct07324837-2026-11-12`, retrieved 2026-11-18)
- Completion: 2029-01-01 (anticipated) (ClinicalTrials.gov record NCT07324837, source copy `cardio:ctgov-nct07324837-2026-11-12`, retrieved 2026-11-18)
- Countries: Russia (ClinicalTrials.gov record NCT07324837, source copy `cardio:ctgov-nct07324837-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07324837-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
- Acronym: FRIDA-CT
- Condition: Ischemic Stroke, Acute
- Intervention (Drug): non-immunogenic staphylokinase
- Intervention (Drug): Placebo
- Lead sponsor: Supergene, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Supergene, LLC (`cardio:org-supergene-llc`)

## Provenance

Content hash: 71e0dfdcf4755c0d943d9f106d7b199a7c047b871726d86292ba21aa8590e598
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
